TheLancetOncol Profile Banner
The Lancet Oncology Profile
The Lancet Oncology

@TheLancetOncol

Followers
61K
Following
1K
Media
2K
Statuses
11K

The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=35·9.

London, NYC, Munich, Beijing
Joined June 2009
Don't wanna be here? Send us removal request.
@TheLancetOncol
The Lancet Oncology
10 days
🚨Our Dec issue is live! - https://t.co/jtWFJdoTSE 📊Articles: #lungcancer, #breastcancer, #hepatocellularcarcinoma, #rectalcancer, #glioma 📑Reviews including neurocognitive outcomes in patients with brain metastases AND SISAQOL-IMI consensus guidelines on PROs in trials
0
9
18
@TheLancetOncol
The Lancet Oncology
9 days
🎧Listen to our Dec podcast with @breastDoktor and @andrepfob discussing the Lucerne Toolbox 3 (📑 https://t.co/gOsH7QSSit), digital health and AI in early breast cancer Spotify: https://t.co/ODNEz8V87P Apple: https://t.co/0B0UdUOYli
@TheLancetOncol
The Lancet Oncology
10 days
🚨Our Dec issue is live! - https://t.co/jtWFJdoTSE 📊Articles: #lungcancer, #breastcancer, #hepatocellularcarcinoma, #rectalcancer, #glioma 📑Reviews including neurocognitive outcomes in patients with brain metastases AND SISAQOL-IMI consensus guidelines on PROs in trials
0
4
9
@Thecoinmedium
Coin Medium
2 months
When No More Bitcoins Are Mined. What Happens? Will Bitcoin survive on fees alone or implode under security risk? Get the roadmap to Bitcoin’s future.
30
11
96
@TheLancetOncol
The Lancet Oncology
10 days
✏️This month's Editorial: Making prostate cancer screening fit for purpose https://t.co/Bo4EDBaxRt
@TheLancetOncol
The Lancet Oncology
10 days
🚨Our Dec issue is live! - https://t.co/jtWFJdoTSE 📊Articles: #lungcancer, #breastcancer, #hepatocellularcarcinoma, #rectalcancer, #glioma 📑Reviews including neurocognitive outcomes in patients with brain metastases AND SISAQOL-IMI consensus guidelines on PROs in trials
0
3
15
@TheLancetOncol
The Lancet Oncology
14 days
🔴Online: Artificial intelligence and radiologists in #pancreaticcancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study https://t.co/Xo0dqTeqX9
6
27
118
@TheLancetOncol
The Lancet Oncology
14 days
The main differential diagnoses for a red patch on palate include pyogenic granuloma, peripheral giant cell granuloma, squamous cell carcinoma, and granulomatosis with polyangiitis and erythroplakia
0
0
1
@DDCityTheMovie
Drop Dead City The Movie
20 days
The city was broke—but not broken. Drop Dead City, the 2025 documentary about NYC’s 1975 fiscal crisis, is out now. Don’t miss this smart, gripping and unexpectedly poignant story of urban survival, now streaming on all major platforms!
0
38
293
@TheLancetOncol
The Lancet Oncology
14 days
The correct answer was C) Amelanotic mucosal melanoma. Despite the complete absence of pigmentation, histopathological examination confirmed mucosal melanoma with characteristic melanocytic proliferation and positive SOX10/PRAME immunostaining.
1
0
2
@TheLancetOncol
The Lancet Oncology
17 days
Check out London Global Cancer Week #LGCW2025, running Nov 24 to Nov 28. https://t.co/d4GHt4oy6O It's a pleasure for @TheLancetOncol to sponsor another year!
0
0
6
@TheLancetOncol
The Lancet Oncology
21 days
News 🗞️Government shutdown and Medicare changes impact cancer care in the USA, reported by Sharmila Devi https://t.co/ceZcULYuFk 🗞️More e-cigarette users than cigarette smokers for the first time in the UK, reported by Manjulika Das https://t.co/Dhd0CCgOgF
0
1
5
@TheLancetOncol
The Lancet Oncology
23 days
Clinical examination revealed a raspberry-like, red patch measuring approximately 1 x 1 cm on the hard palate. What is the correct diagnosis? A) Pyogenic granuloma B) Squamous cell carcinoma C) Amelanotic mucosal melanoma D) Granulomatosis with polyangiitis
1
0
2
@TheLancetOncol
The Lancet Oncology
23 days
❓Clinical picture: A 62-year-old woman with Behçet's syndrome was referred following incidental discovery of a palatal lesion during a dental consultation. By then, the lesion had persisted for two months.
1
0
6
@BrianPPhillips
Brian P. Phillips
26 days
The Pearl Bitcoin fund allows accredited U.S. investors & corporations to leverage the full potential of Bitcoin while eliminating all capital gains taxes after a 10-year hold via our SEC compliant, institutional grade, proprietary IRS approved process.
0
37
463
@LancetGastroHep
The Lancet Gastroenterology & Hepatology
29 days
Our December issue is out now at https://t.co/PqPBcCqeLY Content includes diet in GI disorders; IBS; IBD; oesophageal cancer; alcohol-related liver disease; MASLD + more! #LiverTwitter #GITwitter #MedTwitter
1
5
22
@TheGGTC
GGTC
24 days
🌍 The Global Tobacco Industry Interference Index 2025 is out! How well are governments protecting public health from Big Tobacco’s interference? This fifth edition — our most far-reaching yet — ranks 100 countries on how they’re standing up to industry influence. 👉 See who’s
0
2
5
@TheLancet
The Lancet
24 days
Liver cancer is the 6th most common cancer globally. Join our webinar exploring The Lancet's Commission on addressing the global HCC burden and its comprehensive strategies from prevention to treatment. 👉 Register: https://t.co/FJ5T63p7he #oncology #hepatology #lgcw2025
11
10
40
@TheLancetOncol
The Lancet Oncology
24 days
📊Online now: Effectiveness of NELSON versus PLCOm2012 #lungcancer screening eligibility criteria in Germany (HANSE): a prospective cohort study https://t.co/R3pgyY001S ✏️Comment: Defining eligibility for lung cancer screening based on individual risk https://t.co/mQa7KxvueW
0
0
5
@TheLancetOncol
The Lancet Oncology
24 days
…and this is why the UK needs a fully funded long-term National Cancer Control Plan co-created with experts now. UK Government is failing badly in this regard, lives needlessly lost. See:
Tweet card summary image
bbc.co.uk
Experts say patients are being harmed by cancer diagnosis and treatment delays.
0
1
8
@TheLancetOncol
The Lancet Oncology
25 days
🆕Comment: A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home Authors: @QUBCancerProf, @DrCaryAdams, Eduardo Pisani, @YannickRomero, @sar_quinlan, & @prof_price https://t.co/51ux0IGXv3
1
6
11
@ClerkDev
Clerk
17 days
Scaling SaaS? Clerk gives you RBAC, organization invites, and verified domains. No boilerplate, just results.
0
0
17
@TheLancetOncol
The Lancet Oncology
30 days
🆕Online: Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial https://t.co/pNhwFbpfbT
1
5
10
@TheLancetOncol
The Lancet Oncology
1 month
📽️Watch video on The Human Crisis in Cancer here: https://t.co/r2VCnOU1fA 🎧 In our podcast, Dr Gary Rodin, @gary_rodin, joins us in discussing the Commission: https://t.co/zwluRcwf05
@TheLancetOncol
The Lancet Oncology
1 month
🆕The human crisis in cancer: a Lancet Oncology Commission is now live! The commission warns of a growing human crisis in cancer and calls for a shift towards human-centered care 🖱️Read the Commission here: https://t.co/q4vSzUHLzk
1
10
15
@TheLancetOncol
The Lancet Oncology
1 month
🆕The human crisis in cancer: a Lancet Oncology Commission is now live! The commission warns of a growing human crisis in cancer and calls for a shift towards human-centered care 🖱️Read the Commission here: https://t.co/q4vSzUHLzk
0
10
18
@TheLancetOncol
The Lancet Oncology
1 month
🔴Online: Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 📊Article: https://t.co/Ik4dQFu4kZ ✏️Comment: https://t.co/EA9Fl0lInU
1
10
25
@altcoindesknews
Altcoin Desk
2 days
Tired of chasing every new ticker on X? Build a balanced Altcoin portfolio that survives red days too. Checkout how!
0
0
1